Three new dimeric 2-(2-phenethyl)chromones from the agarwood of Aquilaria malaccensis

IF 1.4 4区生物学 Q4 CHEMISTRY, MEDICINAL

Phytochemistry Letters Pub Date : 2025-02-17 DOI:10.1016/j.phytol.2025.02.003

Xian-Yun Yan , Wei Li , Hao Wang , Wen-Hua Dong , Jun Zeng , Fei Wu , Wen-Li Mei , Lin-Fu Liang , Hao-Fu Dai

引用次数: 0

Abstract

Three unreported 2-(2-phenethyl)chromone dimers, malaccenones A–C (1–3), were isolated and identified from the agarwood Aquilaria malaccensis. These compounds were purified by various column chromatographic techniques, and their structures were elucidated based on the analysis of UV, HRESIMS, 1D and 2D NMR, and ECD spectroscopic data, as well as comparison with literature data. Compounds 1–3 were evaluated for their inhibition effects on nitric oxide production in lipopolysaccharide-stimulated RAW264.7 cells. All of these compounds exhibited anti-inflammatory activity with IC₅₀ values ranging from 21.79 ± 1.05–31.44 ± 1.65 μM.

查看原文本刊更多论文

从马钱子(Aquilaria malaccensis)琼脂中提取的三种新的二聚 2-(2-苯乙基)色酮

从沉香木香中分离鉴定了3个未见报道的2-（2-苯乙基）色素二聚体malaccenones A-C（1-3）。通过不同的柱层析技术对化合物进行纯化，并通过UV、hresms、1D和2D NMR、ECD等光谱数据分析及文献资料比对，对化合物的结构进行了鉴定。化合物1-3对脂多糖刺激RAW264.7细胞一氧化氮生成的抑制作用进行了评价。IC50值为21.79 ± 1.05 ~ 31.44 ± 1.65 μM。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Phytochemistry Letters 生物-生化与分子生物学

CiteScore

3.00

自引率

11.80%

发文量

190

审稿时长

34 days

期刊介绍： Phytochemistry Letters invites rapid communications on all aspects of natural product research including: • Structural elucidation of natural products • Analytical evaluation of herbal medicines • Clinical efficacy, safety and pharmacovigilance of herbal medicines • Natural product biosynthesis • Natural product synthesis and chemical modification • Natural product metabolism • Chemical ecology • Biotechnology • Bioassay-guided isolation • Pharmacognosy • Pharmacology of natural products • Metabolomics • Ethnobotany and traditional usage • Genetics of natural products Manuscripts that detail the isolation of just one new compound are not substantial enough to be sent out of review and are out of scope. Furthermore, where pharmacology has been performed on one new compound to increase the amount of novel data, the pharmacology must be substantial and/or related to the medicinal use of the producing organism.